Zydus Discovery

Zydus Discovery, launched in 2013, caters to Diabetology and Cardiology therapy areas. The division launched Lipaglyn as the country’s first-ever NCE and the world’s first approved Glitazar. Lipaglyn is a unique medicine with both lipid and glucose-lowering effects in one single molecule. Its portfolio includes brands such as OLMY, Pivasta, Sugamet and Twincal for Cardiologists, Diabetologists, Endocrinologists and Physicians.